Wednesday, April 19, 2023 12:30:06 PM
Market Cap Closing In On USD 2 BILLION @ 14.50 per share
https://www.calm-studies.com/#!/
It's Algernon Pharmaceuticals "CEO" who've long since made a comparison of Algernon Pharmaceuticals to what Bellus Health has flawlessly executed in the Chronic Cough area of disease.
It's Algernon Pharmaceuticals "CEO" who sat on the companies best possible chance out the gate (2018/2019) for ALL shareholders to have prospered from the acquisition of it's lead drug IFENPRODIL for Chronic Cough.
It's Algernon Pharmaceuticals "CEO" whose to date still not positioned the company to begin running a standalone Chronic Cough clinical trial for - Yea or Nay - Proof IFENPRODIL is effective at treating Chronic Cough.
It's Algernon Pharmaceuticals "CEO" who told the general public that pursuing Idiopathic Pulmonary Fibrosis was/is a more lucrative route to take for a fledgling pharmaceutical company.
It's Algernon Pharmaceuticals "CEO" whose spent ALL The Money chasing the latest Hot Headline (COVID-19, DMT...) in Pennyland, down a Deep, Dark & Twisted Rabbit Hole, likely to another disastrous conclusion.
What Percentage Of Success (POS) does the "CEO" place on DMT @ Phase 1 or 2...?
It's Algernon Pharmaceuticals "CEO" who spent years kissing the behind of one Kulwant Malhi (King Penny Flipper), and flushing shareholders best interest down the toilet.
Conflicts Of Interest...What Conflicts Of Interest? Who ME ("CEO")?
It's Algernon Pharmaceuticals "CEO" who finds himself at the helm of a company on life support as it tries to raise chump change to keep the lights on @ it's Virtual Offices somewhere throughout Canada.
It's Algernon Pharmaceuticals "CEO" who is counting on YOU to simply let by bygones be bygones, and he's onto bigger and better things for the company, you, and the world at large.
How In The World Algernon Pharmaceuticals "CEO" remains at the helm remains an overwhelming bonkers thought.
Only In Penny World could you tell a story like ^that with a straight face.
STR8 FACE
M$
Yo X! L I F E
Get A Grip On It!
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM